

PROJECT REPORT
FOR
SUNTRIL PHARMACEUTICALS PVT LTD.

INDEX

1 Introduction

- i. Project
- ii. Plant Plans
- iii. Technical know how
- iv. Management & Organization
- v. Raw Material
- vi. Effluent Treatment
- vii. Man power requirement
- viii. Energy Conservation

2. Marketing Arrangement

3. Schedule of Implementation

4. Status of Government Approvals

5. Manufacturing Process

6. Plant & Machinery

7. Utility Schedule

8. Details Of API In Company Pipeline

9. Detail of chemicals in company pipeline

1. Introduction

The project is being promoted by M/s Suntril Pharmaceutical Pvt. Ltd. Plot No. 219, Industrial Area HSIIDC, Alipur, Barwala, with a view to tap tremendous scope of the pharmaceutical industry supported by the following facts. The drugs and pharmaceutical industry has shown significant growth and improvement in profitability. This growth rather is more significant as it has been achieved despite frequent changes made in the drug policy and has been achieved as an outcome of some dynamic strategies adapted by the industry.

The pharmaceutical industry is considered lifeline industry as it is directly concerned with the health of the people. The Indian pharmaceutical industry has registered phenomenal growth since independence from an annual turnover of 10 million; the industry is expected to achieve a turnover of Rs. 20,000 Cr by 2020. India today enjoys the recognition and respect as one of the leading producer of quality pharmaceuticals products and formulations in the world.

In the present scenario every drug industry has to operate under strict norms of ^cGMP governed by Drugs & Cosmetics Act. 1940 in order to maintain quality at par with the global requirement. Hence immense potential in exports is another opportunity for this industry.

The State Government is providing uninterrupted electricity supply at the comparatively cheaper prices. The incentives so granted in the policies will be able to provide the initial push required for establishing the industry. The unit is strongly aiming at kombi pack supply, which is given by Pharmaceutical Industries with Unit is also aiming at promoting its products thro' Wholesale and retail supply to ensure better product mix. Unit is also aiming at Export and Government supply so as to build the volume of the business.

i. Project

The promoters of M/s Suntril Pharmaceutical Pvt. Ltd. Plot No. 219 Industrial Estate HSIIDC, Barwala Dr. Pardeep Narula intend to expand the existing business by way of Manufacturing, Importing, Exporting, buying & selling of all kinds of API intermediates and chemicals as Raw materials. The company is in the process of setting up State of art manufacturing unit at Plot No. 219, Industrial Area HSIIDC, Alipur Barwala


The project is being promoted to cater Commercial market, domestic market, Export & Govt. supply. The city of Haryana provides all necessary facilities viz. link roads, sewerage, sanitary facilities, modern state of the art communication systems, banking and commercial facilities for development of industrial units. The industrial township is well connected with the adjacent states and other part of India through a network of roads, which facilitates traveling as well as transportation of goods both inwards and outwards. This further facilitates the marketing of products anywhere in the country.

There is a regular flow of workers from nearby as well as far off state of Haryana. They are gradually trained in the field of different product lines in various units already established here. Power connection required for the units are easily available especially in Industrial towns promoted by the state government.


M/s Suntril Pharmaceutical Pvt. Ltd. Plot No. 219, Industrial Area HSIIDC, Alipur, Barwala,
Haryana India
Proposed Plans for Floors and Perspective Views-


[illegible]


First Floor:-



3-D View for Ground Floor:



3 D View for First Floor:



The site is well connected by Road and situated in Plot No. 219, Industrial Area HSIIDC, Alipur, Barwala, Haryana where basic infrastructure is available for Industrial set up. The

skilled and semi skilled labor is easily available from nearby areas. Besides the facilities like telephone, Electricity water etc are available at the location.

iii. Arrangement for Technical & Process Know how

The Promoter Dr. Pardeep Narula is already marketing in the same field as a distributor and supplier with all the big companies of API Manufactures in India

In addition to aforesaid, the Promoter Dr. Pardeep Narula is also feeding combipack supply to Pharmaceutical-Oncology Products throughout India for the last 10 years and average sales of Rs. 5 Cr annually. Hence the promoters have good grasp of the technicalities involved in establishing the product line in the market with expert technical and process knowledge to install Manufacturing plant easily available from the experts.

iv. Management & Organization

The concept of Medicare has experienced a subtle transformation in the last few years. Health has begun to be regarded as a vital input for efficiency. Thus health and wellness have become essential for social-economic development as a whole. As the future of Medicine increasingly extends from individual to community M/s Suntril Pharmaceutical Pvt. Ltd. Plot No. 219, Industrial Area HSIIDC, Alipur Barwala has identified twin strategies for growth and consolidation i.e. innovation and Execution. M/s Suntril Pharmaceutical Pvt. Ltd. also believes that sound financial management is essential for maximizing returns. Effective corporate governance will keep the company's policy decision and executive actions under stern scrutiny and observations.

Management's Objectives

a. Integrated Manufacturing Process

Optimum resource utilization will always be on M/s Suntril Pharmaceutical Pvt. Ltd. priorities. This will lead to affordable, dependable qualitative API -products solution for ailing humanity.

b. Assured Quality

Quality will be an intrinsic value of building up the brand and establishing the product in

the market. Dependable systems, consistent processes and well-trained people will lead to reliable quality. It is a culture that strives to better itself all the time. This culture will run through the entire system of the company. Adhering to quality guidance is the trust that will derive API Manufacturers to use medical products with confidence.

c. Strategic Procurement & Sourcing

Effective procurement program play a major role in driving efficiencies in terms of supply assurance, regulatory compliance and cost economics. The extensive use of latest procurement policies, strategic sourcing and professional buying by the executives of the company will help in efficient sourcing of inputs and counter the negative influence of an inflationary market.

d. Imparting Skills Enhancement

M/s Suntril Pharmaceutical Pvt. Ltd. Plot No. 219, Industrial Area HSIIDC, Alipur, Barwala, has set its sight firmly on the future. It realizes that change is inevitable, and is always prepared for change. Ongoing training session and up-gradation of modules will be kept in mind on high priority basis. Regular knowledge advancement initiatives, which will be launched throughout the year, keep everyone from Manager to the field executives geared for every challenge. Every effort is made to:

- a Open up minds to newer ideas and encourage the spirit of R&D.
- b Identify, nurture and enhance talent towards growth.
- c Motivate People.

e. Drive Efficiency

Speed, reliability and reach hold the key to the future. IT strategies will be focused on improving sales force effectiveness, driving supply chain efficiency and employee productivity though workflow automation.

f. Community Development

At M/s Suntril Pharmaceutical Pvt. Ltd, we believe that Social Responsibility is an integral part of our business and inherent in our mission. The company will strive to add value to society, not just in terms of money, but also in terms of time, care and compassion

V Raw Material

The basic Raw Material(s) required for manufacturing products are available from Delhi, Maharashtra, and Hyderabad as well from overseas. M/s Suntril Pharmaceutical Pvt. Ltd. can directly purchase these basic drugs & Raw Material directly from Manufacturers or their C & F/CSA. Alternatively, the products can also be purchased from the local wholesale dealers & international market for export purpose.

VI Effluent Treatment

During the commissioning of the project Suntril is planning to install its own ETP Plant, having capacity of handling **10KL** per day. The water generated from the ETP plant will either discharge into the main drain of HSIIDC or can be recycled for the process. The company will obtain NOC/requisite permissions from Pollution Control Board.

Vii Man Power Requirement

The requirement of Manpower for the project including skilled and unskilled labour including administration persons is estimated at 25 (as per list annexed). The skilled persons shall be employed with the guidance of consultants and shall be impart training to key personnel. Company will employ maximum persons from the State of Haryana.

Viii Energy Conservation

The company also foresees deep commitment to the highest standard in Energy Management and will ensure proper use and its conservation.

2. Marketing Arrangements

India is emerging as Global Powerhouse in API. It is increasingly being recognized as reliable source of quality API at affordable prices.

API segment in India is very competitive sector. Presently price realization has improved, and expected to stabilize in future with rapid increase in growth of pharma industry.

3. Schedule of Implementation

The company expects to complete the project in 5 months time and start commercial production from October 2015. The schedule of implementation is as follows:

<u>Particulars</u>	<u>Time Consumption</u>
Acquisition of Land & Building *	Existing
Plant & Machinery (including partitions)	3.00 Months
Installation and Commissioning	1.50 Months
Trail Run	0.50 Months
Total	5.00 Months

* Company has finalized its rent deed of land and constructed building and also finalized its layout plan with the Architect for renovation and making amendments as required for installing plant and machinery along with utilities.


4. Status of Government Approvals

<u>SN.</u>	<u>Particulars</u>	<u>Status</u>
1.	Registration of Firm	Registered
2.	Registration of HSIIDC	Applied for
3.	Registration under VAT/CST	Applied for
4.	Registration under Excise	Applied for
5.	NOC Country & Town Planning	Applied for
6.	NOC from Pollution Control Board	To be Applied
7.	Sanction of extra Electricity Load	To be Applied
8.	NOC from fire	To be Applied
9.	Manufacturing Drug License	After Completion of Plant To be Applied


5. Manufacturing Process:-

PROCESS FLOW DIAGRAM


Stage – 1: MNT-V to MLS-1



(Manufacturing Area)


Stage – II: MLS-1 to MLS-2

(Manufacturing Area)



(Manufacturing Area)

Stage – IV: MLS – 2 to MLS Sodium in Pharma Area



(Pharma - Area)

6. Plant & Machinery

The company is going to go in for on line production machinery (compact line). All the machines will be cladded with **S.S 304** having contact of **S.S 316 L**. These machines will be strictly as per the guidelines of Schedule M. These latest machine will help in lowering man power requirement. They will help to minimize production losses and achieve highest standards of quality. There are very few installations of such compact lines which will give company the added edge over others. Moreover the production capacity is quite high. This will help the company to win good buyers who generally are big companies. These machines are indigenous & quite cheap as compared to imported ones. The machines are being sourced from reputed & leading manufacturers. They will also train the manpower to efficient run these machines & take proper care of them.

Estimated Cost of The Project
(Rs In Lacs)

Sr. No.	Particulars	Cost
		Rupee Cost
1	Land & Site Development	65.00
2	Buildings	102.22
3	Plant & Machinery (Indigenous)	305.96
4	Miscellaneous Fixed Assets	141.66
5	Pre - Operative Expenses	65.94
6	Provision for Contingencies	30.79
7	Margin For Working Capital	72.82
	Total Cost of Project	784.39

DETAILS OF LAND & SITE DEVELOPMENT

Particulars	AMOUNT
The Company has already acquired Industrial Plot No. 219, measuring 450 Sq.mtr at HSIIDC, Alipur, Barwala, Haryana	65.00
Total	65.00

Estimated Cost of The Building**(Rs. In Lacs)**

Sr.	Description	Length Sq.ft	Bredth Sq.ft	Sq.ft	Floors	Rate/Sq.ft	Amount
A	Civil Construction						100.22
	GRAND TOTAL						100.22
	Add Architects Fees @	2.00%					2.00
	Total Cost						102.22

SUNTRIL PHARMACEUTICALS PRIVATE LIMITED

API MANUFACTURING UNIT

Particulars of Indigenous Machinery

Sr. No.	Description	Qty.	Basic Cost	Total	Excise Duty	Sale Tax @ 2%	Freight	Total Cost	SUPPLIER
A NON BETA LACTAM									
1	Glass Line Reactor - 1000 Litres	2	7.50	15.00	1.85	0.34	0.34	17.53	Pending
2	Stainless Steel Reactor - 1000 Litres	4	5.25	21.00	2.60	0.47	0.48	24.55	Unitech Services
3	Centrifuge Halar coated 24 Inch	2	4.96	9.92	1.23	0.22	0.23	11.60	Shiv Shakti Process Equipment P Ltd
4	VTD of 18 plates	1	10.76	10.76	1.33	0.24	0.25	12.58	Shiv Shakti Process Equipment P Ltd
5	RCVD of 250L	1	6.75	6.75	0.83	0.15	0.15	7.88	Dharma Engineering
6	Sifter	1	1.20	1.20	0.15	0.03	0.03	1.41	Dharma Engineering
7	Micronizer	1	4.00	4.00	0.49	0.09	0.09	4.67	
8	Multimill	1	1.96	1.96	0.24	0.04	0.04	2.28	Shiv Shakti Process Equipment P Ltd
9	Blender - 600 Ltrs	1	3.50	3.50	0.43	0.08	0.08	4.09	MEC-WELL Pharma Machinery Co
10	Weighing Machine Capacity 300kg	5	0.30	1.50	0.19	0.03	0.03	1.75	Aarkey Labtronix India
11	Nutsche filter 100-200 L	1	2.96	2.96	0.37	0.07	0.07	3.47	Shiv Shakti Process Equipment P Ltd
12	Hydrogenator Unit - 100 Litres	1	10.45	10.45	1.29	0.23	0.24	12.21	Amar Equipments P Ltd
13	Vaccum Pump	1	6.00	6.00	0.74	0.13	0.14	7.01	
14	Sparkler 18 Plates	1	3.95	3.95	0.49	0.09	0.09	4.62	Dharma Engineering
								115.65	
B ONCOLOGY PLANT									
1	25L Catch Pot in SS 316 MOC	1	0.45	0.45	0.06	0.01	0.01	0.53	Betochem Consultants & Engineers P Ltd
2	Multi Position Actuated Damper at exhaust	1	0.78	0.78	0.10	0.02	0.02	0.92	Betochem Consultants & Engineers P Ltd
3	Reactor Charge Isolator in SS 316 construction with provision for nitrogen inertisation	1	10.80	10.80	1.33	0.24	0.25	12.62	Betochem Consultants & Engineers P Ltd
4	Isolators for Filtration, Drying, Milling sieving and pack off operations as per technical specifications, FLP with zanier barrier and push button controls	1	51.00	51.00	6.30	1.15	1.17	59.62	Betochem Consultants & Engineers P Ltd
5	VTD (03 Tray) Without Water Circulation System	1	3.30	3.30	0.41	0.07	0.08	3.86	Betochem Consultants & Engineers P Ltd
6	Multi Position Actuated Damper at Exhaust	1	2.34	2.34	0.29	0.05	0.05	2.73	Betochem Consultants & Engineers P Ltd
7	50L catch pot in SS 316 MOC	1	0.55	0.55	0.07	0.01	0.01	0.64	Betochem Consultants & Engineers P Ltd
8	Tool kit	1	1.35	1.35	0.17	0.03	0.03	1.58	Betochem Consultants & Engineers P Ltd
								82.50	
C LABORATORY EQUIPMENTS									
1	Deepali Stirrers LS - 5	6	0.20	1.20	0.15	0.03	0.03	1.41	Deepali United Mfg. P Ltd
2	Buchi Rotavapours - 1 Litres	1	6.43	6.43	0.79	0.14	0.15	7.51	Buchi India P Ltd
3	Analytical Balance 0-1 kg Capacity	3	0.70	2.10	0.26	0.05	0.05	2.46	Aarkey Labtronix India
4	Vacuum Oven	1	1.20	1.20	0.15	0.03	0.03	1.41	Aarkey Labtronix India
5	Vacuum Pumps	3	0.50	1.50	0.19	0.03	0.03	1.75	
6	Laboratory Furniture	1	12.00	12.00	0.00	0.24	0.24	12.48	
7	Ph Meter	2	0.84	1.68	0.21	0.04	0.04	1.97	
8	100L Glass Assembly Units	2	2.50	5.00	0.62	0.11	0.11	5.84	
								34.83	
D QC EQUIPMENTS									
1	HPLC PDA	1	26.40	26.40	3.26	0.59	0.00	30.25	Shimadzu Asia Pacific Pte Ltd
2	GC Head Space	1	18.60	18.60	2.30	0.42	0.00	21.32	PerkinEmler
3	Analytical Balance 100 g Capacity	2	1.05	2.10	0.26	0.05	0.05	2.46	Aarkey Labtronix India
4	Karl Fischer Titremeter	1	2.24	2.24	0.28	0.05	0.05	2.62	Labindia Analytical Instruments P Ltd
5	Vacuum Oven	1	1.20	1.20	0.15	0.03	0.03	1.41	Aarkey Labtronix India
6	Furnace	1	0.20	0.20	0.02	0.00	0.00	0.22	
7	Semi Microbalance 100g capacity	1	2.42	2.42	0.30	0.05	0.06	2.83	Aarkey Labtronix India
8	Millipore Water Generation unit	1	2.53	2.53	0.31	0.06	0.06	2.96	Aarkey Labtronix India
								64.07	
GRAND TOTAL (A+B+C+D)								297.05	
Machinery Erection & Installation (@ 2%)								5.94	
Essential Spares (@ 1%)								2.97	
								305.96	

SUNTRIL PHARMACEUTICALS PRIVATE LIMITED

API MANUFACTURING UNIT

Particulars of Misc. Fixed Assets

Sr. No.	Description	Qty.	Rate	Amount	Supplier
A	UTILITIES				
1	RO Water Unit 1000 Litres	1.00	5.75	5.75	Paul Water Treatment Services
2	CHW and CHB system	1.00	20.00	20.00	
3	Boiler of 0.6 -0.8 tone	1.00	5.85	5.85	
4	ETP Plant	1.00	5.00	5.00	Paul Water Treatment Services
5	Fire Hydrant System	1.00	5.00	5.00	
6	HVAC System	1.00	25.00	25.00	
7	Air curtains, Washing Machine, Fridge etc	1.00	2.00	2.00	
8	Evaporator	1.00	5.00	5.00	
9	Piping	Lot	15.00	15.00	
10	Cheker Plate	Lot	15.00	15.00	
	ELECTRICALS				
11	Servo Voltage Stabilizer 315 KVA	1.00	4.25	4.25	Power Electronic Equipments
12	DG Set - 125KV	1.00	10.00	10.00	
13	Transformer - 315 KVA	1.00	3.16	3.16	Power Electronic Equipments
14	Cable -Wires-Lights-Control panels	1.00	14.15	14.15	
15	LT Panels	1.00	8.00	8.00	
	Total (B)			143.16	
	GRAND TOTAL (A+B)			143.16	

7. Utility Schedule

Total require sanction load	= 300 KVA
Average consumption	= 150 units per hour
Average consumption	= 150* 24 = 3600 units per day
Fuel consumption: Diesel	= 36* 24 = 864 Ltr per day

8. DETAILS OF API IN COMPANY PIPELINE

A. NON BETA LACTAM DRUGS

Thiocolchicoside

Thiocolchicoside (Muscoril, Myoril, Neoflax) is a muscle relaxant with anti-inflammatory and analgesic effects. It acts as a competitive GABAA receptor antagonist and also glycine receptor antagonist with similar potency and nicotinic acetylcholine receptors to a much lesser extent.] It has powerful convulsant activity and should not be used in seizure-prone individuals.

Montelukast sodium

Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is usually administered orally. Montelukast is a CysLT antagonist; that it blocks the action of leukotriene D₄ (and secondary ligands LTC₄ and LTE₄) on the cysteinyl leukotriene receptor CysLT₁ in the lungs and bronchial tubes by binding to it. This reduces the bronchoconstriction otherwise caused by the leukotriene and results in less inflammation.

Febuxostat

Febuxostat is a urate lowering drug, an inhibitor of oxidase that is indicated for use in the treatment of hyperuricemia and gout. A study comparing febuxostat to allopurinol found that more individuals treated with febuxostat had decreased levels of uric acid but there was no difference in the amount of initial gout flares or the surface area of gout tophi. A committee of the British National Institute for Health and Clinical Excellence concluded that although febuxostat had been shown to be more effective than fixed-dose (300 mg) allopurinol in lowering serum uric acid concentration, it had not been shown to be clinically more efficacious or cost effective compared with allopurinol when taken to control uric acid levels (up to 900 mg). However, the committee recommended febuxostat for people who are intolerant of allopurinol.

Mycophenolate Mofetil / Sodium

Mycophenolic acid or mycophenolate is an immunosuppressant drug used to prevent rejection in organ transplantation. It inhibits an enzyme needed for the growth of T cells and B cells. It was initially marketed as the prodrug mycophenolate mofetil (MMF) to improve oral bioavailability. More recently, the salt mycophenolate sodium has also been introduced.

Pentazocine

Pentazocine is a synthetically prepared prototypical mixed agonist-antagonist narcotic (opioid analgesic) drug of the benzomorphan class of opioids used to treat moderate to moderately severe pain. This compound may exist as one of two enantiomers, named (+)-pentazocine and (-)-pentazocine. (-)-pentazocine is a κ opioid receptor agonist, while (+)-pentazocine is not, instead displaying a ten-fold greater affinity for the σ receptor.

B. ONCOLOGY DRUGS**Capecitabine**

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of numerous cancers. Capecitabine is a prodrug, that is enzymatically converted to 5-fluorouracil (5-FU) in the body.

Gemcitabine

Gemcitabine (pronunciation: jem-SITE-a-been) is a nucleoside analog used as chemotherapy.

Irinotecan

Irinotecan is a drug used for the treatment of cancer. Irinotecan prevents DNA from unwinding by inhibition of topoisomerase. In chemical terms, it is a semisynthetic analogue of the natural alkaloid camptothecin. Its main use is in colon cancer, in particular, in combination with other chemotherapy agents. This includes the regimen FOLFIRI, which

consists of infusional 5-fluorouracil, leucovorin, and irinotecan.

Sunitinib

Sunitinib (marketed as Sutent by Pfizer, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006.

Sunitinib was the first cancer drug simultaneously approved for two different indications. Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and FLT3.

Uramustine

Uramustine (INN) or uracil mustard is a chemotherapy drug which belongs to the class of alkylating agents. It is used in lymphatic malignancies such as non-Hodgkin's lymphoma. It works by damaging DNA, primarily in cancer cells that preferentially take up the uracil due to their need to make nucleic acids during their rapid cycles of cell division. The DNA damage leads to apoptosis of the affected cells. Bone marrow suppression and nausea are the main side effects. Chemically it is a derivative of nitrogen mustard and uracil. Uramustine is an alkylating agent of the nitrogen mustard type. Uracil mustard is a bifunctional alkylating agent, and is cell cycle-phase nonspecific. Activity occurs as a result of formation of an unstable ethyleniminium ion.

9. Detail of chemicals in company pipeline

2-[3-cyano-4-(2-methylpropoxy)phenyl]4-methylthiazole-5-carboxylic acid; 2-[3-Cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid
CAS: 144060-53-7

Ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylate
160844-75-7

4-Hydroxybenzene-1-carbothioamide
25984-63-8

Pentyl [1-(3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1H-pyrimidin-4-yl]carbamate
CAS: 154361-50-9

-1,2,3-Tri-O-acetyl-5-deoxy-D-ribose
62211-93-2

-2',3'-di-O-acetyl-5'-deoxy-5-fluorocytidine
161599-46-8

-5'-deoxy-5-fluoro-n-[(pentyloxy)carbonyl]cytidine 2',3'-diacetate
162204-20-8

(R,E)-2-(1-((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propylthio)methyl)cyclopropyl)acetic acid
158966-92-8

Methyl-[E]-3-[3-[2-(7-chloro-2-quinolinyl) ethenyl] phenyl]-3-oxo-propyl]benzoate
MTN6
149968-11-6

Methyl-[E]-2-[3S-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-hydroxy propyl] benzoate
MT7
181139-72-0

[(S)-(E)]-2-[3-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-hydroxypropyl]-phenyl-2-propanol
MT8
142569-70-8

1-(Mercaptomethyl) cyclopropane acetic acid
MTS4

162515-68-6

(1-mercaptomethyl) cyclopropane methyl acetate

MTS5

152922-73-1

1-(hydroxymethyl)cyclopropylacetonitrile

MTS2

152922-71-9

(2RS,6RS,11RS)-6,11-dimethyl-3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol

359-83-1

1-benzyl-2-(4-methoxybenzyl)-3,4-dimethyl-1,2-dihydropyridine

1-benzyl-6-(4-methoxybenzyl)-3,4-dimethyl-1,2,3,6-tetrahydropyridine oxalate

(2R, 6R, 11R)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-benzyl-2,6-methano-3-benzazocin-8-ol

(2R, 6R, 11R)-1, 2, 3, 4, 5, 6-hexahydro-6, 11-dimethyl-2, 6-Methano-3-benzazocin-8-ol

N-(2-(Diethylamino) ethyl)-5-formyl-2, 4-dimethyl-1H-pyrrole-3-carboxamide

590424-04-7

N-[2-(Diethylamino) ethyl]-2,4-dimethyl-1H-pyrrole-3-Carboxamide

590424-05-8

4-(ethoxycarbonyl)-3,5-dimethyl-1H-pyrrole-2-carboxylic acid

5442-91-1

5-((Z)-(5-fluoro-2-oxoindolin-3-ylidene) methyl)-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid

356068-93-4

N-(2-(Diethylamino) ethyl)-5-formyl-2, 4-dimethyl-1H-pyrrole-3-carboxamid

356068-86-5

5-Fluoro-2-oxindole

56341-41-4

N-Desacetyl-N-formyl Thiocolchicoside

219547-29-2
